Jacquelyn L S Hanson1, Marios Arvanitis1, Clarissa M Koch1, John L Berk1, Frederick L Ruberg1, Tatiana Prokaeva1, Lawreen H Connors2. 1. From the Amyloidosis Center (J.L.S.H., C.M.K., J.L.B., F.L.R., T.P., L.H.C.), Department of Pathology and Laboratory Medicine (J.L.S.H., C.M.K., L.H.C.), Department of Medicine (M.A., J.L.B., F.L.R.), and Section of Cardiovascular Medicine, Department of Medicine (F.L.R.), Boston University School of Medicine, MA. The current affiliation for C.M.H. is the Department of Medicine, Division of Pulmonary and Critical Care, Northwestern University, Chicago, IL. 2. From the Amyloidosis Center (J.L.S.H., C.M.K., J.L.B., F.L.R., T.P., L.H.C.), Department of Pathology and Laboratory Medicine (J.L.S.H., C.M.K., L.H.C.), Department of Medicine (M.A., J.L.B., F.L.R.), and Section of Cardiovascular Medicine, Department of Medicine (F.L.R.), Boston University School of Medicine, MA. The current affiliation for C.M.H. is the Department of Medicine, Division of Pulmonary and Critical Care, Northwestern University, Chicago, IL. lconnors@bu.edu.
Abstract
BACKGROUND: Wild-type transthyretin amyloidosis (ATTRwt), an underappreciated cause of heart failure in older adults, is challenging to diagnose and monitor in the absence of validated, disease-specific biomarkers. We examined the prognostic use and survival association of serum TTR (transthyretin) concentration in ATTRwt. METHODS AND RESULTS: Patients with biopsy-proven ATTRwt were retrospectively identified. Serum TTR, cardiac biomarkers, and echocardiographic parameters were assessed at baseline and follow-up evaluations. Statistical analyses included Kaplan-Meier method, Cox proportional hazard survival models, and receiver-operating characteristic curve analysis. Median serum TTR concentration at presentation was 23 mg/dL (n=116). Multivariate predictors of shorter overall survival were decreased TTR, left ventricular ejection fraction and elevated cTn-I (cardiac troponin I); an inclusive model demonstrated superior accuracy in 4-year survival prediction by receiver-operating characteristic curve analysis (area under the curve, 0.77). TTR values lower than the normal limit, <18 mg/dL, were associated with shorter survival (2.8 versus 4.1 years; P=0.03). Further, TTR values at 1- and 2-year follow-ups were significantly lower (P<0.001) in untreated patients (n=23) compared with those treated with TTR stabilizer, diflunisal (n=12), after baseline evaluation. During 2-year follow-up, unchanged TTR corresponded to increased cTn-I (P=0.006) in untreated patients; conversely, the diflunisal-treated group showed increased TTR (P=0.001) and stabilized cTn-I and left ventricular ejection fraction at 1 year. CONCLUSIONS: In this series of biopsy-proven ATTRwt, lower baseline serum TTR concentration was associated with shorter survival as an independent predictor of outcome. Longitudinal analysis demonstrated that decreasing TTR corresponded to worsening cardiac function. These data suggest that TTR may be a useful prognostic marker and predictor of outcome in ATTRwt.
BACKGROUND: Wild-type transthyretin amyloidosis (ATTRwt), an underappreciated cause of heart failure in older adults, is challenging to diagnose and monitor in the absence of validated, disease-specific biomarkers. We examined the prognostic use and survival association of serum TTR (transthyretin) concentration in ATTRwt. METHODS AND RESULTS:Patients with biopsy-proven ATTRwt were retrospectively identified. Serum TTR, cardiac biomarkers, and echocardiographic parameters were assessed at baseline and follow-up evaluations. Statistical analyses included Kaplan-Meier method, Cox proportional hazard survival models, and receiver-operating characteristic curve analysis. Median serum TTR concentration at presentation was 23 mg/dL (n=116). Multivariate predictors of shorter overall survival were decreased TTR, left ventricular ejection fraction and elevated cTn-I (cardiac troponin I); an inclusive model demonstrated superior accuracy in 4-year survival prediction by receiver-operating characteristic curve analysis (area under the curve, 0.77). TTR values lower than the normal limit, <18 mg/dL, were associated with shorter survival (2.8 versus 4.1 years; P=0.03). Further, TTR values at 1- and 2-year follow-ups were significantly lower (P<0.001) in untreated patients (n=23) compared with those treated with TTR stabilizer, diflunisal (n=12), after baseline evaluation. During 2-year follow-up, unchanged TTR corresponded to increased cTn-I (P=0.006) in untreated patients; conversely, the diflunisal-treated group showed increased TTR (P=0.001) and stabilized cTn-I and left ventricular ejection fraction at 1 year. CONCLUSIONS: In this series of biopsy-proven ATTRwt, lower baseline serum TTR concentration was associated with shorter survival as an independent predictor of outcome. Longitudinal analysis demonstrated that decreasing TTR corresponded to worsening cardiac function. These data suggest that TTR may be a useful prognostic marker and predictor of outcome in ATTRwt.
Authors: Graham Lohrmann; Alexandra Pipilas; Roberta Mussinelli; Deepa M Gopal; John L Berk; Lawreen H Connors; Nirupama Vellanki; Jennifer Hellawell; Omar K Siddiqi; Jonathan Fox; Mathew S Maurer; Frederick L Ruberg Journal: J Card Fail Date: 2019-12-02 Impact factor: 5.712
Authors: Cecília Monteiro; Jaleh S Mesgazardeh; João Anselmo; Joana Fernandes; Marta Novais; Carla Rodrigues; Gabriel J Brighty; David L Powers; Evan T Powers; Teresa Coelho; Jeffery W Kelly Journal: JCI Insight Date: 2019-06-20
Authors: Xin Jiang; Richard Labaudinière; Joel N Buxbaum; Cecília Monteiro; Marta Novais; Teresa Coelho; Jeffery W Kelly Journal: Proc Natl Acad Sci U S A Date: 2021-03-02 Impact factor: 11.205
Authors: Marcus V Simões; Fabio Fernandes; Fabiana G Marcondes-Braga; Philip Scheinberg; Edileide de Barros Correia; Luis Eduardo P Rohde; Fernando Bacal; Silvia Marinho Martins Alves; Sandrigo Mangini; Andréia Biolo; Luis Beck-da-Silva; Roberta Shcolnik Szor; Wilson Marques Junior; Acary Souza Bulle Oliveira; Márcia Waddington Cruz; Bruno Vaz Kerges Bueno; Ludhmila Abrahão Hajjar; Aurora Felice Castro Issa; Felix José Alvarez Ramires; Otavio Rizzi Coelho Filho; André Schmidt; Ibraim Masciarelli Francisco Pinto; Carlos Eduardo Rochitte; Marcelo Luiz Campos Vieira; Cláudio Tinoco Mesquita; Celso Dario Ramos; José Soares-Junior; Minna Moreira Dias Romano; Wilson Mathias Junior; Marcelo Iório Garcia Junior; Marcelo Westerlund Montera; Marcelo Dantas Tavares de Melo; Sandra Marques E Silva; Pedro Manoel Marques Garibaldi; Aristóteles Comte de Alencar Neto; Renato Delascio Lopes; Diane Xavier de Ávila; Denizar Viana; José Francisco Kerr Saraiva; Manoel Fernandes Canesin; Glaucia Maria Moraes de Oliveira; Evandro Tinoco Mesquita Journal: Arq Bras Cardiol Date: 2021-09 Impact factor: 2.000
Authors: Omar K Siddiqi; Yuliya Y Mints; John L Berk; Lawreen Connors; Gheorghe Doros; Deepa M Gopal; Shivangi Kataria; Graham Lohrmann; Alexandra R Pipilas; Frederick L Ruberg Journal: Amyloid Date: 2022-01-27 Impact factor: 6.571
Authors: Sebastiaan Hc Klaassen; Dirk J van Veldhuisen; Hans LA Nienhuis; Maarten P van den Berg; Bouke Pc Hazenberg; Peter van der Meer Journal: Card Fail Rev Date: 2020-08-07